We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.76B
1-Year Est. Return 62.41%
This Fund
S&P 500
This Quarter Est. Return
+13.49%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$3.34B
AUM Growth
-$346M
Cap. Flow
-$728M
Cap. Flow %
-21.78%
Top 10 Hldgs %
68.3%
Holding
475
New
106
Increased
41
Reduced
44
Closed
201

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$447M
2
CYBR
CyberArk
CYBR
+$424M
3
GTLS
Chart Industries
GTLS
+$243M
4
IPG
Interpublic Group of Companies
IPG
+$96.3M
5
COOP
Mr. Cooper
COOP
+$67.2M

Top Sells

Rank Stock Value
1
WBA
Walgreens Boots Alliance
WBA
+$288M
2
SKX
Skechers
SKX
+$227M
3
BPMC
Blueprint Medicines
BPMC
+$220M
4
CHX
ChampionX
CHX
+$187M
5
ANSS
Ansys
ANSS
+$173M

Sector Composition

Rank Sector Weight
1 Technology 21.6%
2 Industrials 16.01%
3 Healthcare 15.52%
4 Communication Services 12.09%
5 Financials 10.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
401
PTC Therapeutics
PTCT
$5.78B
– –
-14,548
Closed -$711K
PTGX icon
402
Protagonist Therapeutics
PTGX
$9.43B
– –
-14,523
Closed -$803K
QURE icon
403
CALL
uniQure
QURE
$3.09B
– –
-80,000
Closed -$124K
QURE icon
404
uniQure
QURE
$3.09B
– –
-63,475
Closed -$885K
RARE icon
405
CALL
Ultragenyx Pharmaceutical
RARE
$1.51B
– –
-60,000
Closed -$238K
RARE icon
406
Ultragenyx Pharmaceutical
RARE
$1.51B
– –
-31,861
Closed -$1.16M
RCUS icon
407
Arcus Biosciences
RCUS
$3.78B
– –
-52,975
Closed -$431K
REPL icon
408
CALL
Replimune Group
REPL
$1.42B
– –
-169,000
Closed -$308K
REPL icon
409
Replimune Group
REPL
$1.42B
– –
-114,082
Closed -$1.06M
RIGL icon
410
Rigel Pharmaceuticals
RIGL
$909M
– –
-104,890
Closed -$1.96M
RLAY icon
411
Relay Therapeutics
RLAY
$4.17B
– –
-127,036
Closed -$440K
RZLT icon
412
Rezolute
RZLT
$441M
– –
-455,701
Closed -$2.03M
SDGR icon
413
Schrodinger
SDGR
$1.5B
– –
-24,358
Closed -$490K
SE icon
414
Sea Limited
SE
$68.7B
– –
-6,800
Closed -$1.09M
SHW icon
415
Sherwin-Williams
SHW
$81B
– –
-15,800
Closed -$5.43M
SKX
416
DELISTED
Skechers
SKX
– –
-3,598,177
Closed -$227M
SLNO
417
CALL
DELISTED
Soleno Therapeutics
SLNO
– –
-10,000
Closed -$74.5K
SLNO
418
DELISTED
Soleno Therapeutics
SLNO
– –
-10,362
Closed -$868K
SLNO
419
PUT
DELISTED
Soleno Therapeutics
SLNO
– –
-12,000
Closed -$40.2K
SNDX icon
420
Syndax Pharmaceuticals
SNDX
$1.84B
– –
-90,441
Closed -$847K
SRRK icon
421
Scholar Rock
SRRK
$6.74B
– –
-25,426
Closed -$901K
SWTX
422
DELISTED
SpringWorks Therapeutics
SWTX
– –
-1,385,517
Closed -$65.1M
TARS icon
423
Tarsus Pharmaceuticals
TARS
$3.98B
– –
-11,000
Closed -$446K
TECK icon
424
Teck Resources
TECK
$33.9B
– –
-90,000
Closed -$3.63M
TERN
425
DELISTED
Terns Pharmaceuticals
TERN
– –
-273,619
Closed -$1.02M
15 16
17
18 19

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return
JCM
Janney Capital Management Pittsburgh, Pennsylvania $1.59B AUM 23.25% 1-Year Est. Return
MPM
Meritage Portfolio Management Overland Park, Kansas $1.51B AUM 26.61% 1-Year Est. Return

UBS O'Connor's Q3 2025 Portfolio in Review

As of Q3 2025, UBS O'Connor held 475 positions worth $3.34B, down 9.4% from $3.69B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

UBS O'Connor withdrew a net $728M in Q3 2025, closing 201 positions and reducing 44 holdings. Its most notable exit was Walgreens Boots Alliance, an estimated $288M position sold in full.

By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 14% a quarter earlier, followed by Industrials and Healthcare.

Against the trend, UBS O'Connor opened a new position in Verona Pharma worth $457M.

  • UBS O'Connor's largest Q3 2025 buy was Verona Pharma: 4,283,462 shares worth $457M.
  • UBS O'Connor added most to Interpublic Group of Companies in Q3 2025, an estimated $96.3M increase.
  • UBS O'Connor's biggest Q3 2025 reduction was Kellanova, cutting an estimated $110M.
  • UBS O'Connor fully exited Walgreens Boots Alliance in Q3 2025, selling an estimated $288M.
  • UBS O'Connor's ten largest holdings make up 68% of its $3.34B portfolio in Q3 2025.
  • UBS O'Connor opened 106 new positions and closed 201 in Q3 2025.
  • UBS O'Connor's portfolio value fell 9.4% quarter-over-quarter to $3.34B.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.